DOCSLIB.ORG

BIOTIN (BIOTINIDASE) DEFICIENCY Marc E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BIOTIN (BIOTINIDASE) DEFICIENCY Marc E BIOTIN (BIOTINIDASE) DEFICIENCY Marc E. Tischler, PhD; University of Arizona BIOTIN (BIOTINIDASE) DEFICIENCY •biotininthebodyisrecycledbyitsremovalfromcarboxylaseenzymestowhichitisattached(Fig.1) •fourcarboxylasereactionsinthebodyrequirebiotin: pyruvate carboxylase (Figure 2): o required for glucose production; inactivity lowers blood sugar (hypoglycemia) o lactic acid not used for making glucose accumulates (lactic acidosis; lactic acidemia) acetyl-CoA carboxylase (Figure 3): o required for biosynthesis of fatty acids by liver and fat cells o lowers availability of stored fatty acids for exercise (weak muscles; hypotonia) propionyl-CoA carboxylase (Figure 4): o required for breakdown of certain amino acids (i.e., isoleucine, valine, methionine, threonine) and fatty acids with an odd number of carbons o leads to formation of propionic acid and hydroxypropionic acid (acidosis) o leads to formation of methylcitrate that interferes with normal functioning of citric acid cycle, lowering cell energy production especially in the brain (developmental delays) -methylcrotonyl-CoA carboxylase (Figure 5): o required for breakdown of leucine o formation of methylcrotonic acid that leads to hydroxyvaleric acid, which reacts with carnitine; lowered carnitine diminishes oxidation of fatty acids for energy production o methylcrotonic acid combines with glycine which is excreted in the urine (methylcrotonylglycinuria) NORMAL BIOTIN CYCLE DISEASE Carboxylases Biotin (PC, ACC, PCC, MCC) Lysine +biotin Holocarboxylase synthetase Biotin Cycle Holo-carboxylases Biotin Cycle (biotin activated) Biocytin Biotin not recycled Various decreased amount available Biotinidase proteases Amino acids Figure 1. Though biotin is taken in from the diet, recycling via the biotin cycle is essential for maintaining adequate amounts. In the biotin cycle (left), the four carboxylase enzymes (pyruvate carboxylase, PC; acetyl-CoA carboxylase, ACC; propionyl-CoA carboxylase, PCC; methycrotonyl-CoA carboxylase, MCC) become active by acquiring biotin, which is attached to a lysine (amino acid) on each enzyme. Biotin is released by breaking down these enzyme via proteases. The action of proteases releases biotin still attached to its lysine, termed biocytin. Biocytin is cleaved by biotinidase to produce free biotin and lysine. In biotin deficiency due to biotinidase defect, the biotin cycle loses function (X). Hence biotin becomes relatively deficient and supplements must be provided. EFFECT OF BIOTIN (BIOTINIDASE) DEFICIENCY ON PYRUVATE CARBOXYLASE IN LIVER CELLS NORMAL DISEASE Lactic acid provides carbons BLOOD Lactic acid for glucose Less used for glucose biosynthesis biosynthesis accumulation = lactic acidosis) Lactic dehydrogenase Pyruvic acid Pyruvic acid Pyruvate +biotin carboxylase Oxaloacetate X Multiple enzymes Glucose biosynthesis Figure 2. Normally in liver cells, lactic acid is metabolized to form glucose using pyruvate carboxylase (left). In biotinidase deficiency, the decreased amounts of biotin cause a lower activity of pyruvate carboxylase (X). Instead lactic acid accumulates in the blood (lactic acidosis). This adds to the acidosis problem caused by accumulation of other acids in this disease (see Figures 4-6) . EFFECT OF BIOTIN (BIOTINIDASE) DEFICIENCY ON ACETYL-CoA CARBOXYLASE IN LIVER AND FAT CELLS NORMAL DISEASE Glucose provides carbons for fatty acid Glucose biosynthesis Multiple enzymes Acetyl-CoA Acetyl-CoA Acetyl-CoA +biotin carboxylase Malonyl-CoA X Fatty acid Lack of stored fats for muscle fuel synthase Fatty acid biosynthesis Triglycerides fat storage Figure 3. Normally in liver and fat cells, glucose is metabolized to form fatty acids using acetyl-CoA carboxylase (left). In biotinidase deficiency, the decreased amounts of biotin cause a lower activity of acetyl- CoA carboxylase (X). Instead glucose is diverted to other functions. However decreased formation of fatty acids reduces their storage and availability for exercise, hence the weak muscles and hypotonia. EFFECT OF BIOTIN (BIOTINIDASE) DEFICIENCY ON DISEASE NORMAL PROPIONYL-CoA CARBOXYLASE Methionine, Isoleucine, Methionine, Isoleucine, Valine, Threonine, Valine, Threonine, Odd-chain fatty acids Odd-chain fatty acids Many various enzymes Propionyl-CoA Propionyl-CoA +biotin Propionyl-CoA carboxylase Methylmalonyl-CoAX Methylmalonyl-CoA Methylmalonyl- Propionic acid Citric acidosis CoA mutase Acid Succinyl-CoA XCycle Citric Enzyme names for Methylcitrate Acid Usable indicated arrow blocks citric acid Cycle energy cycle function Figure 4. Metabolism of 4 amino acids and odd-chain fatty acids all depend on propionyl-CoA carboxylase. Propionyl- CoA is metabolized ultimately to succinyl-CoA that enters the citric acid cycle, which produces usable energy for the cell. In biotinidase deficiency, the decreased amounts of biotin cause a lower activity of propionyl-CoA carboxylase (X) so that propionyl-CoA accumulates. Propionyl-CoA is instead converted to propionic acid that causes acidosis,a life-threatening condition. Propionyl-CoA also is processed, by an enzyme in the citric acid cycle, to methylcitrate. Methylcitrate blocks normal functioning of the citric acid cycle to limit energy output, especially in brain cells that require large amounts of energy. Low activity of propionyl-CoA carboxylase can, in rare instances, be due to poor interaction with biotin so that providing more of this biotin may have some benefits in treatment. EFFECT OF BIOTIN (BIOTINIDASE) DEFICIENCY ON DISEASE NORMAL 3-METHYLCROTONYL-CoA CARBOXYLASE Leucine Leucine Leucine aminotransferase -Ketoisocaproic acid -Ketoisocaproic acid -Ketoacid dehydrogenase Isovaleryl-CoA Isovaleryl-CoA Isovaleryl-CoA dehydrogenase 3-Methylcrotonyl-CoA 3-Methylcrotonyl-CoA Methylcrotonyl- +biotin CoA carboxylase (MCC) X 3-Methylcrotonic acid 3-Methylglutaconyl-CoA Several enzymes +glycine Usable energy Acetyl-CoA 3-Methylcrotonylglycine Enzyme names for excreted in urine indicated arrow 3-methylcrotonylglycinuria Figure 5. Leucine is metabolized in cells to acetyl-CoA that is then converted to usable energy. In biotinidase deficiency, the decreased amounts of biotin cause a lower activity of methylcrotonyl-CoA carboxylase (MCC) (X) so that 3-methylcrotonyl-CoA accumulates. 3-Methylcrotonyl-CoA is converted to 3-methylcrotonic acid. One fate of 3-methylcrotonic acid is combining with glycine to form 3-methylcrotonylglycine that is excreted in the urine (3- methylcrotonylglycinuria). Other consequences of the disease are depicted in Figs 6 and 7). DIMINISHED FAT OXIDATION DUE TO LOWER MCC ACTIVITY WITH BIOTINIDASE DEFICIENCY NORMAL 3-Methylcrotonyl-CoA Fatty acids oxidized Usable energy produced +carnitine for cell processes Acetyl-CoA Acetyl-CoA (e.g., glucose biosynthesis) DISEASE 3-Methylcrotonyl-CoA 3-Hydroxyisovaleric acid Fatty acids excreted in urine depleted 3-Methylcrotonic acid 3-hydroxyisovaleric aciduria carnitine Acetyl-CoA abnormal use X of carnitine Less usable 3-Hydroxyisovaleryl- energy produced carnitine Figure 6. In biotinidase deficiency (lower), the lower activity of MCC leads to formation of 3-methylcrotonic acid, which is modified to 3-hydroxyisovaleric acid. These two acids cause acidosis and potential neurological damage. 3- Hydroxyisovaleric acid combines with carnitine to form 3-hydroxyisovaleryl-carnitine. This latter reaction lowers the amount of carnitine in patients. Carnitine is essential for fatty acid oxidation (upper) to produce energy that is required for cell processes, such as biosynthesis of glucose (blood sugar). The potential depletion of carnitine in untreated biotinidase deficiency can cause impairment of fatty acid oxidation (X) leading to less usable energy for cell processes. HYPOGLYCEMIA AND LACTIC ACIDEMIA DUE TO LOWER MCC ACTIVITY WITH BIOTINIDASE DEFICIENCY IN LIVER CELLS NORMAL Lactic acid Usable energy is produced for Glucose biosynthesis provides carbons cell processes such as glucose Fatty acids for glucose biosynthesis biosynthesis DISEASE Fatty acids Lactic acid Glucose production Less used for glucose biosynthesis X X accumulation = lactic acidemia) Less usable energy produced Figure 7. Normally the oxidation of fatty acids produces usable energy that can power the biosynthesis of glucose with the carbons coming from lactic acid (upper). As noted in Fig. 6, in biotinidase deficiency the oxidation of fatty acids potentially is lowered leading to less usable energy for cell processes such as glucose biosynthesis.Decreasedproductionofglucoseleadstoaloweramountofbloodglucose(hypoglycemia). Lactic acid normally provides carbons for glucose biosynthesis (upper). In biotinidase deficiency (lower) because there is less usable energy to power glucose biosynthesis, less lactic acid is used for producing glucose. Instead blood lactic acid can accumulate (lactic acidemia). This adds to the acidosis problem caused by 3-methylcrotonic acid and 3-hydroxyisovaleric acid (see Fig. 5)..
Load more

Recommended publications
  • Counsyl Foresight™ Carrier Screen Disease List
    COUNSYL FORESIGHT™ CARRIER SCREEN DISEASE LIST The Counsyl Foresight Carrier Screen focuses on serious, clinically-actionable, and prevalent conditions to ensure you are providing meaningful information to your patients. 11-Beta-Hydroxylase- Bardet-Biedl Syndrome, Congenital Disorder of Galactokinase Deficiency Deficient Congenital Adrenal BBS1-Related (BBS1) Glycosylation, Type Ic (ALG6) (GALK1) Hyperplasia (CYP11B1) Bardet-Biedl Syndrome, Congenital Finnish Nephrosis Galactosemia (GALT ) 21-Hydroxylase-Deficient BBS10-Related (BBS10) (NPHS1) Gamma-Sarcoglycanopathy Congenital Adrenal Bardet-Biedl Syndrome, Costeff Optic Atrophy (SGCG) Hyperplasia (CYP21A2)* BBS12-Related (BBS12) Syndrome (OPA3) Gaucher Disease (GBA)* 6-Pyruvoyl-Tetrahydropterin Bardet-Biedl Syndrome, Cystic Fibrosis GJB2-Related DFNB1 Synthase Deficiency (PTS) BBS2-Related (BBS2) (CFTR) Nonsyndromic Hearing Loss ABCC8-Related Beta-Sarcoglycanopathy and Deafness (including two Cystinosis (CTNS) Hyperinsulinism (ABCC8) (including Limb-Girdle GJB6 deletions) (GJB2) Muscular Dystrophy, Type 2E) D-Bifunctional Protein Adenosine Deaminase GLB1-Related Disorders (SGCB) Deficiency (HSD17B4) Deficiency (ADA) (GLB1) Biotinidase Deficiency (BTD) Delta-Sarcoglycanopathy Adrenoleukodystrophy: GLDC-Related Glycine (SGCD) X-Linked (ABCD1) Bloom Syndrome (BLM) Encephalopathy (GLDC) Alpha Thalassemia (HBA1/ Calpainopathy (CAPN3) Dysferlinopathy (DYSF) Glutaric Acidemia, Type 1 HBA2)* Canavan Disease Dystrophinopathies (including (GCDH) (ASPA) Alpha-Mannosidosis Duchenne/Becker Muscular
    [Show full text]
  • Child Neurology: Hereditary Spastic Paraplegia in Children S.T
    RESIDENT & FELLOW SECTION Child Neurology: Section Editor Hereditary spastic paraplegia in children Mitchell S.V. Elkind, MD, MS S.T. de Bot, MD Because the medical literature on hereditary spastic clinical feature is progressive lower limb spasticity B.P.C. van de paraplegia (HSP) is dominated by descriptions of secondary to pyramidal tract dysfunction. HSP is Warrenburg, MD, adult case series, there is less emphasis on the genetic classified as pure if neurologic signs are limited to the PhD evaluation in suspected pediatric cases of HSP. The lower limbs (although urinary urgency and mild im- H.P.H. Kremer, differential diagnosis of progressive spastic paraplegia pairment of vibration perception in the distal lower MD, PhD strongly depends on the age at onset, as well as the ac- extremities may occur). In contrast, complicated M.A.A.P. Willemsen, companying clinical features, possible abnormalities on forms of HSP display additional neurologic and MRI abnormalities such as ataxia, more significant periph- MD, PhD MRI, and family history. In order to develop a rational eral neuropathy, mental retardation, or a thin corpus diagnostic strategy for pediatric HSP cases, we per- callosum. HSP may be inherited as an autosomal formed a literature search focusing on presenting signs Address correspondence and dominant, autosomal recessive, or X-linked disease. reprint requests to Dr. S.T. de and symptoms, age at onset, and genotype. We present Over 40 loci and nearly 20 genes have already been Bot, Radboud University a case of a young boy with a REEP1 (SPG31) mutation. Nijmegen Medical Centre, identified.1 Autosomal dominant transmission is ob- Department of Neurology, PO served in 70% to 80% of all cases and typically re- Box 9101, 6500 HB, Nijmegen, CASE REPORT A 4-year-old boy presented with 2 the Netherlands progressive walking difficulties from the time he sults in pure HSP.
    [Show full text]
  • Nutrition 102 – Class 3
    Nutrition 102 – Class 3 Angel Woolever, RD, CD 1 Nutrition 102 “Introduction to Human Nutrition” second edition Edited by Michael J. Gibney, Susan A. Lanham-New, Aedin Cassidy, and Hester H. Vorster May be purchased online but is not required for the class. 2 Technical Difficulties Contact: Erin Deichman 574.753.1706 [email protected] 3 Questions You may raise your hand and type your question. All questions will be answered at the end of the webinar to save time. 4 Review from Last Week Vitamins E, K, and C What it is Source Function Requirement Absorption Deficiency Toxicity Non-essential compounds Bioflavonoids: Carnitine, Choline, Inositol, Taurine, and Ubiquinone Phytoceuticals 5 Priorities for Today’s Session B Vitamins What they are Source Function Requirement Absorption Deficiency Toxicity 6 7 What Is Vitamin B1 First B Vitamin to be discovered 8 Vitamin B1 Sources Pork – rich source Potatoes Whole-grain cereals Meat Fish 9 Functions of Vitamin B1 Converts carbohydrates into glucose for energy metabolism Strengthens immune system Improves body’s ability to withstand stressful conditions 10 Thiamine Requirements Groups: RDA (mg/day): Infants 0.4 Children 0.7-1.2 Males 1.5 Females 1 Pregnancy 2 Lactation 2 11 Thiamine Absorption Absorbed in the duodenum and proximal jejunum Alcoholics are especially susceptible to thiamine deficiency Excreted in urine, diuresis, and sweat Little storage of thiamine in the body 12 Barriers to Thiamine Absorption Lost into cooking water Unstable to light Exposure to sunlight Destroyed
    [Show full text]
  • TITLE: Biotinidase Deficiency PRESENTER: Anna Scott Slide 1
    TITLE: Biotinidase Deficiency PRESENTER: Anna Scott Slide 1: Hello, my name is Anna Scott. I am a biochemical genetics laboratory director at Seattle Children’s Hospital. Welcome to this Pearl of Laboratory Medicine on “Biotinidase Deficiency.” Slide 2: Lecture Overview For today’s Pearl, I will start with background information about biotinidase including its role in metabolism and clinical features. Then we will discuss different clinical assays that can detect and diagnose the enzyme deficiency. Finally, I will touch on biotinidase as it relates to newborn screening. Slide 3: Background Biotinidase deficiency is an inborn error of metabolism, specifically affecting biotin metabolism. Biotin is also known as vitamin B7. Most free biotin is absorbed through the gut from food. This vitamin is an essential cofactor for four carboxylase enzymes. Biotin metabolism primarily consists of two steps- 1) loading the free biotin into an apocarboxylase to form the active form of the enzyme, called holocarboylases and 2) recycling biocytin back to lysine and free biotin after protein degradation. The enzyme responsible for loading free biotin into new enzymes is holocarboxylase synthetase. Loss of function of this enzyme can cause clinical features similar to biotinidase deficiency, typically with an earlier age of onset and greater severity. Biotinidase deficiency results in failure to recycle biocytin back to free biotin for re-incorporation into a new apoenzyme. Slide 4: Clinical Symptoms and Therapy © 2016 Clinical Chemistry Pearls of Laboratory Medicine Title Classical clinical symptoms associated with biotinidase deficiency include: alopecia, eczema, hearing and/or vision loss, and acidosis. During acute illness, hyperammonemia, seizures, and coma can also manifest.
    [Show full text]
  • Biotinidase Deficiency: a Survey of 10 Cases
    Arch Dis Child: first published as 10.1136/adc.63.10.1244 on 1 October 1988. Downloaded from Archives of Disease in Childhood, 1988, 63, 1244-1249 Biotinidase deficiency: a survey of 10 cases H J WASTELL,* K BARTLET,t G DALE,* AND A SHEIN *Department of Clinical Biochemistry, Newcastle General Hospital, and tDepartments of Child Health and Clinical Biochemistry, Newcastle University Medical School, Newcastle upon Tyne SUMMARY Ten patients with biotinidase deficiency were studied. Clinical findings at presenta- tion varied with dermatological signs (dermatitis and alopecia), neurological abnormalities (fits, hypotonia, and ataxia), and recurrent infections being the most common features, although none of these occurred in every case. Biochemically the disease is characterised by metabolic acidosis and organic aciduria. Treatment with biotin results in pronounced, rapid, clinical and biochemical improvement, but some patients have residual neurological damage comprising neurosensory hearing loss, visual pathway defects, ataxia, and mental retardation. The cause of this permanent damage remains obscure and it is not clear if the early introduction of treatment will prevent it. Biotin is a cofactor required by acetyl CoA carboxy- a functional biotin deficiency (biotinidase deficiency) lase (ACC) [EC 6.4.1.2], pyruvate carboxylase (PC) caused by failure to recycle endogenous biotin and [EC 6.4.1.1], propionyl CoA carboxylase (PCC) to liberate dietary biotin, or by defective biotinylation copyright. [EC 6.4.1.3] and 3 methylcrotonyl CoA carboxylase of apocarboxylase because of a mutant holocarboxy- (MCC) [EC 6.4.1.4.].' It is covalently attached to lase synthetase that has an increased Km with the apocarboxylases by the epsilon amino group of a respect to biotin.
    [Show full text]
  • Bone Disorder and Reduction of Ascorbic Acid Concentration Induced by Biotin Deficiency in Osteogenic Disorder Rats Unable to Synthesize Ascorbic Acid
    J. Clin. Biochem. Nutr., 12, 171-182, 1992 Bone Disorder and Reduction of Ascorbic Acid Concentration Induced by Biotin Deficiency in Osteogenic Disorder Rats Unable to Synthesize Ascorbic Acid Yuji FURUKAWA,1,* Akiko KINOSHITA,1,•õ1 Hiroichi SATOH,1,•õ2 Hiroko KIKUCHI,1, •õ3 Shoko OHKOSHI,1,•õ4 Masaru MAEBASHI,2 Yoshio MAKINO,3 Takao SATO,4 Michiko ITO,1 and Shuichi KIMURA1 1 Laboratory of Nutrition, Department of Food Chemistry, Faculty of Agriculture, Tohoku University, Aoba-ku, Sendai 981, Japan 2 The Second Department of Internal Medicine, School of Medicine, Tohoku University, Aoba-ku, Sendai 980, Japan 3 Makino Dermatology Clinic, Aoba-ku, Sendai 981, Japan 4 Division of Internal Medicine, National Sendai Hospital, Miyagino-ku, Sendai 983, Japan (Received January 13, 1992) Summary The developmental mechanism of the bone disorder in- duced by biotin deficiency was studied in osteogenic disorder rats, animals that have a hereditary defect in ascorbic acid-synthesizing ability. The osteogenic disorder rats fed a biotin-deficient diet containing raw egg white were afflicted with bone abnormality including a hunch in the vertebral column. In the case of biotin deficiency, although the ascorbic acid content in the diet was in excess of the required amount, ascorbic acid levels of the plasma and the organs in the rats were significant lower than those of control rats. This suggests that the bone disorder induced by biotin deficiency in the rats may result from the promotion of ascorbic acid consumption or the impairment of ascorbic acid incorporation in the animal tissues. Key Words: osteogenic disorder rat, biotin deficiency, ascorbic acid, bone disorder, acetyl-CoA carboxylase Biotin serves as an essential cofactor for four carboxylases, namely, acetyl- *To whom correspondence should be addressed .
    [Show full text]
  • Biotin Fact Sheet for Consumers
    Biotin Fact Sheet for Consumers What is biotin and what does it do? Biotin is a B-vitamin found in many foods. Biotin helps turn the carbohydrates, fats, and proteins in the food you eat into the energy you need. How much biotin do I need? The amount of biotin you need each day depends on your age. Average daily recommended amounts are listed below in micrograms (mcg). Life Stage Recommended Amount Birth to 6 months 5 mcg Infants 7–12 months 6 mcg Children 1–3 years 8 mcg Children 4–8 years 12 mcg Biotin is naturally present in some Children 9–13 years 20 mcg foods, such as salmon and eggs. Teens 14–18 years 25 mcg Adults 19+ years 30 mcg Pregnant teens and women 30 mcg Breastfeeding teens and women 35 mcg What foods provide biotin? Many foods contain some biotin. You can get recommended amounts of biotin by eating a variety of foods, including the following: • Meat, fish, eggs, and organ meats (such as liver) • Seeds and nuts • Certain vegetables (such as sweet potatoes, spinach, and broccoli) What kinds of biotin dietary supplements are available? Biotin is found in some multivitamin/multimineral supplements, in B-complex supplements, and in supplements containing only biotin. Am I getting enough biotin? Most people get enough biotin from the foods they eat. However, certain groups of people are more likely than others to have trouble getting enough biotin: • People with a rare genetic disorder called “biotinidase deficiency” • People with alcohol dependence • Pregnant and breastfeeding women 2 • BIOTIN FACT SHEET FOR CONSUMERS What happens if I don’t get enough biotin? Biotin and healthful eating Biotin deficiency is very rare in the United States.
    [Show full text]
  • Biotinidase Deficiency (Biot) Family Fact Sheet
    BIOTINIDASE DEFICIENCY (BIOT) FAMILY FACT SHEET What is a positive newborn screen? What problems can biotinidase deficiency Newborn screening is done on tiny samples of blood cause? taken from your baby’s heel 24 to 36 hours after birth. The blood is tested for rare, hidden disorders that may Biotinidase deficiency is different for each child. Some affect your baby’s health and development. The children have a mild, partial biotinidase deficiency with newborn screen suggests your baby might have a few health problems, while other children may have disorder called biotinidase deficiency. complete biotinidase deficiency with serious complications. A positive newborn screen does not mean your If biotinidase deficiency is not treated, a child might baby has biotinidase deficiency, but it does mean develop: your baby needs more testing to know for sure. • Muscle weakness • Hearing loss You will be notified by your primary care provider or • Vision (eye) problems the newborn screening program to arrange for • Hair loss additional testing. • Skin rashes What is biotinidase deficiency? • Seizures • Developmental delay Biotinidase deficiency affects an enzyme needed to It is very important to follow the doctor’s instructions free biotin (one of the B vitamins) from the food we for testing and treatment. eat, so it can be used for energy and growth. What is the treatment for biotinidase A person with biotinidase deficiency doesn’t have deficiency? enough enzyme to free biotin from foods so it can be used by the body. Biotinidase deficiency can be treated. Treatment is life- long and includes: Biotinidase deficiency is a genetic disorder that is • Daily biotin vitamin pill(s) or liquid.
    [Show full text]
  • Biotinidase Deficiency
    orphananesthesia Anaesthesia recommendations for patients suffering from Biotinidase deficiency Disease name: Biotinidase deficiency ICD 10: E53.8 Synonyms: Late-Onset Biotin-aesponsive Multiple Carboxylase Deficiency, Late-Onset Multiple Carboxylase Deficiency Disease summary: Biotinidase deficiency (BD), biotin metabolism disorder, was first described in 1982 [1]. It is inherited as an autosomal recessive trait. The incidence of BD in the world is approximately 1/60.000 newborns [1]. Clinical manifestations include neurological abnormalities (seizures, ataxia, hypotonia, developmental delay, hearing loss and vision problems like optic atrophy), dermatological abnormalities (seborrheic dermatitis, alopecia, skin rash, conjunctivitis, candidiasis, hair loss), neuromuscular abnormalities (motor limb weakness, spastic paresis, myelopathy), metabolic abnormalities (ketolactic acidosis, organic aciduria, hyperammonemia) [1-6]. Besides, respiratory problems (apnoea, dyspnoea, tachyponea, laryngeal stridor) and immune deficiency findings (prolonged or recurrent viral/fungal infections) are associated with BD [1,3,4]. Hypotonia and seizures are the most common clinical features [4,7]. Medicine in progress Perhaps new knowledge Every patient is unique Perhaps the diagnostic is wrong Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net 1 Disease summary Treatment with 5-10 mg of oral biotin per day results rapidly in clinical and biochemical improvement. However, once vision problems, hearing loss, and developmental delay occur, these problems are usually irreversible even if the child is on biotin therapy [4]. Moreover, BD can lead to coma and death when the child if not treated [8]. In some children, especially after puberty, biotin dose is increased from 10 mg per day to 20 mg per day.
    [Show full text]
  • Case Report Biotinidase Deficiency: Early Presentation
    Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online) Sch. J. App. Med. Sci., 2016; 4(2D):614-617 ISSN 2347-954X (Print) ©Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com Case Report Biotinidase Deficiency: Early Presentation Saumya Chaturvedi, Jayashree Nadkarni*, Rashmi Randa, Shweta Sharma, Rajesh Tikkas Department of Paediatrics, Gandhi Medical College and Associated Kamla Nehru and Hamidia Hospital, Bhopal (M.P.) India *Corresponding author Dr. Jayashree Nadkarni Email: [email protected] Abstract: A 2 month old male child presented with fever, seizures, metabolic acidosis, alopecia and dermatitis. Diagnosed to be case of biotinidase enzyme deficiency. Identification of this disorder is important as it is easily treatable and the patients show dramatic response to therapy. It can prove fatal if not diagnosed. Keywords: alopecia, dermatitis, biotinidase enzyme deficiency. INTRODUCTION and needed ventilation. He was diagnosed as having Biotinidase recycles the vitamin biotin. meningitis after CSF examination. Biotinidase deficiency is a rare metabolic disorder with autosomal recessive inheritance which can cause On examination, patient was found to have dermatological manifestations and lead to severe loss of eyelashes, excessive hair fall, and multiple neurological sequelae if untreated. The symptoms can episodes of myoclonic jerks, dermatitis and be successfully treated or prevented by administering conjunctivitis which the mother had noticed since pharmacological doses of biotin. Holocarboxylase around 1 month of life. He was treated synthetase deficiency also has similar manifestations symptomatically, followed by anticonvulsant therapy and needs to be differentiated. with phenytoin. Convulsions improved and after two days he was removed from ventilator and put on It was first described by Wolf and colleagues intranasal oxygen.
    [Show full text]
  • Newborn Screening FACT SHEET
    Newborn Screening FACT SHEET What is newborn screening? Blood spot screening checks babies for: Arginemia Newborn screening is a set of tests that check babies Argininosuccinate acidemia for serious, rare disorders. Most of these disorders Beta ketothiolase deficiency cannot be seen at birth but can be treated or helped Biopterin cofactor defects (2 types) if found early. The three tests include blood spot, Biotinidase deficiency hearing, and pulse oximetry screening. Carnitine acylcarnitine translocase deficiency Carnitine palmitoyltransferase deficiency (2 types) Carnitine uptake defect Citrullinemia (2 types) Blood spot screening checks for over Congenital adrenal hyperplasia 50 rare but treatable disorders. Early Congenital hypothyroidism Cystic fibrosis detection can help prevent serious health Dienoyl-CoA reductase deficiency problems, disability, and even death. Galactokinase deficiency The box on the right lists the disorders Galactoepimerase deficiency screened for in Minnesota. Galactosemia Glutaric acidemia (2 types) Hearing screening checks for hearing Hemoglobinopathy variants loss in the range where speech is heard. Homocystinuria Hypermethioninemia Identifying hearing loss early helps babies Hyperphenylalaninemia stay on track with speech, language, and Isobutyryl-CoA dehydrogenase deficiency communication skills. Isovaleric acidemia Long-chain hydroxyacyl-CoA dehydrogenase deficiency Pulse oximetry screening checks for a set Malonic acidemia of serious, life-threatening heart defects Maple syrup urine disease known as
    [Show full text]
  • Human Vitamin and Mineral Requirements
    Human Vitamin and Mineral Requirements Report of a joint FAO/WHO expert consultation Bangkok, Thailand Food and Agriculture Organization of the United Nations World Health Organization Food and Nutrition Division FAO Rome The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations concerning the legal status of any country, territory, city or area or of its authorities, or concern- ing the delimitation of its frontiers or boundaries. All rights reserved. Reproduction and dissemination of material in this information product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holders. Applications for such permission should be addressed to the Chief, Publishing and Multimedia Service, Information Division, FAO, Viale delle Terme di Caracalla, 00100 Rome, Italy or by e-mail to [email protected] © FAO 2001 FAO/WHO expert consultation on human vitamin and mineral requirements iii Foreword he report of this joint FAO/WHO expert consultation on human vitamin and mineral requirements has been long in coming. The consultation was held in Bangkok in TSeptember 1998, and much of the delay in the publication of the report has been due to controversy related to final agreement about the recommendations for some of the micronutrients. A priori one would not anticipate that an evidence based process and a topic such as this is likely to be controversial.
    [Show full text]